<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600743</url>
  </required_header>
  <id_info>
    <org_study_id>07-101</org_study_id>
    <nct_id>NCT00600743</nct_id>
  </id_info>
  <brief_title>Effect of a CCK-1R Agonist on Food Intake in Humans</brief_title>
  <acronym>GSK</acronym>
  <official_title>Effect of a CCK-1R Agonist on Food Intake in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK)
      agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia
      Nervosa. The study will be conducted in phases. First, an effective dose for reducing food
      intake, when normal subjects eat normally will be attained. Next, it will be determined
      whether intake at this dose is reduced in control subjects instructed to eat to capacity. If
      the dose is still effective compared to placebo, the same dose will be tested in patients
      with bulimia nervosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study tests the hypothesis that an oral CCK antagonist GSKI181771X will reduce the size
      of a binge meal. It was intended to study the effects of increasing doses on antagonist on
      normal individuals to find an effective dose in a non-binge meal before moving to a binge
      meal. Once the effects of the antagonist on a binge meal were found, the compound would be
      used on patients with bulimia nervosa. However, the product expired and more was not
      available before the patients were tested. Data are presented for the normal participants who
      were instructed to eat normally, followed by a group that was instructed to binge eat.
      Comparisons were made between groups with different instructions and between binge and normal
      meals.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Drug expired before was completed.
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Food Intake for 4 mg Dose of CCK Agonist vs Placebo Meal Conditions</measure>
    <time_frame>25-30 min after taking drug</time_frame>
    <description>Food Intake at 25-30 min after having drug or placebo under normal and binge eating instructions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fullness Rating</measure>
    <time_frame>25-30 min after taking drug</time_frame>
    <description>rating of &quot;How full do you feel&quot; by marking the feeling on a 150 mm line anchored at one end from 0 (not at all) to 150 (most imaginable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sickness Report</measure>
    <time_frame>25-30 min after drug or placebo</time_frame>
    <description>Response to question &quot;How sick do you feel&quot; measured on a 150 mm line anchored by none at all (0 mm left end) and extremely (150 mm right end)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bulimia</condition>
  <arm_group>
    <arm_group_label>1 'Instructions to eat normally'</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>'Instructions to eat normally' Placebo 1 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 'Instructions to eat normally'</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 'Instructions to eat normally'</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>'Instructions to eat normally' 2 mg placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 'Instructions to eat normally'</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 'Instructions to eat normally'</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>'Instructions to eat normally' 4 mg placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 'Instructions to eat normally'</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 Instructions to binge eat</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Instructions to binge eat 4 mg placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 Instructions to binge eat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSKI181771X (CCK-1R agonist)</intervention_name>
    <description>Drug one trial vs placebo</description>
    <arm_group_label>2 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>4 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>6 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>8 Instructions to binge eat</arm_group_label>
    <other_name>GSKI181771X</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Instructions to binge eat</intervention_name>
    <description>Subjects will be instructed to binge eat and will also be given either drug or placebo</description>
    <arm_group_label>7 Instructions to binge eat</arm_group_label>
    <arm_group_label>8 Instructions to binge eat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Instructions to eat normally</intervention_name>
    <description>Subjects will be instructed to eat normally and will also be given either drug or placebo</description>
    <arm_group_label>1 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>2 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>3 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>4 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>5 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>6 'Instructions to eat normally'</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug one trial vs placebo</description>
    <arm_group_label>1 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>3 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>5 'Instructions to eat normally'</arm_group_label>
    <arm_group_label>7 Instructions to binge eat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both controls and patients will be female, 18 to 45 years old, and within 80-120% of
             ideal body weight (Metropolitan Life Insurance, 1983). Inclusion and exclusion will be
             evaluated using the following guidelines:

        Normal Controls:

          -  No current or past psychiatric illness

          -  No history of binge eating or vomiting

          -  80-120% ideal weight

          -  Of non-childbearing potential (i.e. physiologically incapable of becoming pregnant or
             surgically sterile)

          -  If of childbearing potential, willing to use an acceptable method of birth-control
             (please see list in &quot;Exclusion&quot; section)

        Patients with Bulimia Nervosa:

          -  DSM-IV (diagnostic statistical manual - American Psychiatric Association) criteria for
             bulimia nervosa

          -  Duration of illness &gt; 1 year

          -  Purging after binges via self-induced vomiting

        (Same as controls for remaining inclusion criteria)

        Exclusion Criteria:

        Normal Controls:

          -  Significant medical illness: CBC, Chem-1, serum electrolytes (sodium, potassium,
             chloride, CO2), glucose, BUN (blood urea nitrogen), creatinine, Alk Phos, ALT (SGPT),
             AST (SGOT), LDH, total bilirubin, total protein, albumin, globulin, A/G ratio,
             calcium, phosphorus, uric acid, cholesterol, triglyceride

          -  ALT outside of upper limit of normal: Chem-1

          -  History of gallstones, pancreatitis or cholecystitis

          -  Current medication

          -  Hypersensitivity to benzodiazepines (contraindication in DCSI v02, 1-March-2006)

          -  Drug or alcohol abuse in last 3 mts

          -  Pregnancy

          -  Unable or unwilling to use highly effective methods of contraception for the duration
             of the study until an insignificant amount of the investigational product remains in
             the subject (i.e. at least 5 terminal phase half-lives). Examples of highly effective
             methods of contraception are:

               -  Implants of levonorgestrel, or

               -  Injectable progestogen, or

               -  Oral birth control pills for at least 3 monthly cycles prior to administration of
                  study drug + continuation for 24 hrs after last dose of study drug, or

               -  Double-barrier method (e.g. condom, diaphragm) with spermicide

        Note-Significant medical illness is any illness requiring continued care, i.e. chronic
        medication. Examples include hypertension, diabetes, and systemic lupus erythematosis.
        Subjects with seasonal allergies or occasional urinary tract infections will be included.

        Patients with Bulimia Nervosa:

          -  Same as controls
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry R. Kissileff, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeanine Albu, MD</last_name>
    <role>Study Director</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's/Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nyorc.org</url>
    <description>studies</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <results_first_submitted>February 21, 2011</results_first_submitted>
  <results_first_submitted_qc>April 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2017</results_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eating</keyword>
  <keyword>Food Intake</keyword>
  <keyword>Appetite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bulimia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment at St. Luke's Hospital from 2/22/08 through 2/19/09</recruitment_details>
      <pre_assignment_details>Subject had to rate test food greater than 6 on a 9 point scale of liking and have BMI between 19 and 27</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 MG CCK AGONIST NORMAL EATING</title>
          <description>Healthy/normal control participants were given both the 1 mg oral cholecystokinin (CCK) agonist (GSKI181771X) and placebo interventions at separate times in a 2 way crossover study design. After ingesting the CCK agonist or placebo, they were instructed to eat until they felt normally full.</description>
        </group>
        <group group_id="P2">
          <title>2 MG CCK AGONIST NORMAL EATING</title>
          <description>Healthy/normal control participants were given both the 2 mg oral cholecystokinin (CCK) agonist (GSKI181771X) and placebo interventions at separate times in a 2 way crossover study design. After ingesting the CCK agonist or placebo, they were instructed to eat until they felt normally full.</description>
        </group>
        <group group_id="P3">
          <title>4 MG CCK AGONIST NORMAL EATING</title>
          <description>Healthy/normal control participants were given both the 4mg oral cholecystokinin (CCK) agonist (GSKI181771X) and placebo interventions at separate times in a 2 way crossover study design. After ingesting the CCK agonist or placebo, they were instructed to eat until they felt normally full.</description>
        </group>
        <group group_id="P4">
          <title>4 MG CCK AGONIST BINGE EATING</title>
          <description>Healthy/normal control participants were given both the 4 mg oral cholecystokinin (CCK) agonist (GSKI181771X) and placebo interventions at separate times in a 2 way crossover study design. After ingesting the CCK agonist or placebo, they were instructed to binge eat as much as they could.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 MG CCK AGONIST NORMAL EATING</title>
          <description>Healthy/normal control participants were given both the 1 mg oral cholecystokinin (CCK) agonist (GSKI181771X) and placebo interventions at separate times in a 2 way crossover study design. After ingesting the CCK agonist or placebo, they were instructed to eat until they felt normally full.</description>
        </group>
        <group group_id="B2">
          <title>2 MG CCK AGONIST NORMAL EATING</title>
          <description>Healthy/normal control participants were given both the 2 mg oral cholecystokinin (CCK) agonist (GSKI181771X) and placebo interventions at separate times in a 2 way crossover study design. After ingesting the CCK agonist or placebo, they were instructed to eat until they felt normally full.</description>
        </group>
        <group group_id="B3">
          <title>4 MG CCK AGONIST NORMAL EATING</title>
          <description>Healthy/normal control participants were given both the 4mg oral cholecystokinin (CCK) agonist (GSKI181771X) and placebo interventions at separate times in a 2 way crossover study design. After ingesting the CCK agonist or placebo, they were instructed to eat until they felt normally full.</description>
        </group>
        <group group_id="B4">
          <title>4 MG CCK AGONIST BINGE EATING</title>
          <description>Healthy/normal control participants were given both the 4 mg oral cholecystokinin (CCK) agonist (GSKI181771X) and placebo interventions at separate times in a 2 way crossover study design. After ingesting the CCK agonist or placebo, they were instructed to binge eat as much as they could.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="10.96"/>
                    <measurement group_id="B2" value="26.25" spread="3.0"/>
                    <measurement group_id="B3" value="23.75" spread="10.77"/>
                    <measurement group_id="B4" value="24.00" spread="11.64"/>
                    <measurement group_id="B5" value="24.65" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Food Intake for 4 mg Dose of CCK Agonist vs Placebo Meal Conditions</title>
        <description>Food Intake at 25-30 min after having drug or placebo under normal and binge eating instructions</description>
        <time_frame>25-30 min after taking drug</time_frame>
        <population>Subjects had to complete all trials of the protocol successfully</population>
        <group_list>
          <group group_id="O1">
            <title>Binge_4mg Drug</title>
            <description>Non-bulimic controls Instruction to binge eat (7 subjects) drug</description>
          </group>
          <group group_id="O2">
            <title>Normal_1mg Drug</title>
            <description>Eat normally 1 mg dose drug</description>
          </group>
          <group group_id="O3">
            <title>Normal_2mg Drug</title>
            <description>Eat normally 2 mg dose drug</description>
          </group>
          <group group_id="O4">
            <title>Normal_4mg Drug</title>
            <description>Eat normally 4 mg dose drug</description>
          </group>
          <group group_id="O5">
            <title>Binge - 4mg Placebo</title>
            <description>Non-bulimic controls instruction to binge eat - placebo</description>
          </group>
          <group group_id="O6">
            <title>Normal 1 mg Dose Placebo</title>
            <description>Eat normally 1 mg dose placebo</description>
          </group>
          <group group_id="O7">
            <title>Normal_2 mg Dose Placebo</title>
            <description>Eat normally 2 mg dose placebo</description>
          </group>
          <group group_id="O8">
            <title>Normal_4 mg Dose Placebo</title>
            <description>Eat normally 4 mg dose placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Food Intake for 4 mg Dose of CCK Agonist vs Placebo Meal Conditions</title>
          <description>Food Intake at 25-30 min after having drug or placebo under normal and binge eating instructions</description>
          <population>Subjects had to complete all trials of the protocol successfully</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385.69" spread="29.35"/>
                    <measurement group_id="O2" value="447.7" spread="38.64"/>
                    <measurement group_id="O3" value="489.63" spread="45.54"/>
                    <measurement group_id="O4" value="293.79" spread="65.58"/>
                    <measurement group_id="O5" value="532.87" spread="53.4"/>
                    <measurement group_id="O6" value="468.73" spread="74"/>
                    <measurement group_id="O7" value="442.43" spread="61.79"/>
                    <measurement group_id="O8" value="421.98" spread="69.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>t test following ANOVA for difference between drug and placebo - There were 3 doses, and the value reported is for the highest and only effective dose</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>The overall error term was used to compare differences between placebo and drug</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>128.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>41.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fullness Rating</title>
        <description>rating of &quot;How full do you feel&quot; by marking the feeling on a 150 mm line anchored at one end from 0 (not at all) to 150 (most imaginable).</description>
        <time_frame>25-30 min after taking drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Binge_4mg d</title>
            <description>Binge_4mg drug</description>
          </group>
          <group group_id="O2">
            <title>Normal_1mg d</title>
            <description>Normal_1mg drug</description>
          </group>
          <group group_id="O3">
            <title>Normal_2mg d</title>
            <description>Normal_2mg drug</description>
          </group>
          <group group_id="O4">
            <title>Normal_4mg d</title>
            <description>Normal_4mg drug</description>
          </group>
          <group group_id="O5">
            <title>Binge - 4mg Plc</title>
            <description>binge - 4mg placebo</description>
          </group>
          <group group_id="O6">
            <title>Normal 1 mg Placebo</title>
            <description>Normal 1 mg dose placebo</description>
          </group>
          <group group_id="O7">
            <title>Normal 2mg_placebo</title>
            <description>Normal 2mg_dose_placebo</description>
          </group>
          <group group_id="O8">
            <title>Normal_4mg Placebo</title>
            <description>Normal_4mg_dose placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fullness Rating</title>
          <description>rating of &quot;How full do you feel&quot; by marking the feeling on a 150 mm line anchored at one end from 0 (not at all) to 150 (most imaginable).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.14" spread="1.82"/>
                    <measurement group_id="O2" value="101" spread="9.74"/>
                    <measurement group_id="O3" value="128.75" spread="9.84"/>
                    <measurement group_id="O4" value="103.13" spread="17.22"/>
                    <measurement group_id="O5" value="117.57" spread="14.64"/>
                    <measurement group_id="O6" value="79.75" spread="24.29"/>
                    <measurement group_id="O7" value="131.25" spread="9.15"/>
                    <measurement group_id="O8" value="126" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Each group was compared separately in an overall ANOVA with all dose groups included. The results are presented for the groups which received 4 mg dose and instructions to eat normally (normal group) or to binge eat (binge group). The test is the interaction between drug and group i.e. drug effect difference (placebo minus drug) in fullness between the group instructed to binge and the group instructed to eat normally.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.033</p_value>
            <p_value_desc>t-test after ANOVA with repeated measures on placebo minus drug (within groups) between binge and normal instructions (between groups)</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>This was part of an overall ANOVA (SAS proc mixed) with all four groups (3 doses eat normally. 4 ng dose, binge eat) and the error term had 76 df.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>49.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>22.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sickness Report</title>
        <description>Response to question &quot;How sick do you feel&quot; measured on a 150 mm line anchored by none at all (0 mm left end) and extremely (150 mm right end)</description>
        <time_frame>25-30 min after drug or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Binge_4mg Drug</title>
            <description>Non-bulimic controls Instruction to binge eat (7 subjects) drug</description>
          </group>
          <group group_id="O2">
            <title>Normal_1mg Drug</title>
            <description>Eat normally 1 mg dose drug</description>
          </group>
          <group group_id="O3">
            <title>Normal_2mg Drug</title>
            <description>Eat normally 2 mg dose drug</description>
          </group>
          <group group_id="O4">
            <title>Normal_4mg Drug</title>
            <description>Eat normally 4 mg dose drug</description>
          </group>
          <group group_id="O5">
            <title>Binge - 4mg Placebo</title>
            <description>Non-bulimic controls instruction to binge eat - placebo</description>
          </group>
          <group group_id="O6">
            <title>Normal 1 mg Dose Placebo</title>
            <description>Eat normally 1 mg dose placebo</description>
          </group>
          <group group_id="O7">
            <title>Normal_2 mg Dose Placebo</title>
            <description>Eat normally 2 mg dose placebo</description>
          </group>
          <group group_id="O8">
            <title>Normal_4 mg Dose Placebo</title>
            <description>Eat normally 4 mg dose placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sickness Report</title>
          <description>Response to question &quot;How sick do you feel&quot; measured on a 150 mm line anchored by none at all (0 mm left end) and extremely (150 mm right end)</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.57" spread="22.48"/>
                    <measurement group_id="O2" value="21" spread="14.58"/>
                    <measurement group_id="O3" value="10" spread="7.07"/>
                    <measurement group_id="O4" value="17.5" spread="9.64"/>
                    <measurement group_id="O5" value="61.14" spread="20.79"/>
                    <measurement group_id="O6" value="3" spread="1.35"/>
                    <measurement group_id="O7" value="10" spread="8.72"/>
                    <measurement group_id="O8" value="17.25" spread="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Tests the difference between drug and placebo for group = binge instructions</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.014</p_value>
            <p_value_desc>p-value is based on ANOVA with all groups and conditions and is a planned comparison</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>33.4286</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.134</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>df = 53. 26 Used proc GLMMIX in SAS 9.4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Length of the study - 2 - 4 weeks</time_frame>
      <desc>There were no adverse events reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Normal</title>
          <description>Normal control group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The provider of the drug (not sponsor - since this was an investigator initiated protocol) needs to review the results before release. In this case there was a public presentation at a scientific meeting, and the abstract was published. However, before a full report can be released, the provider of the drug needs to review the report.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No adverse events - Some subjects reported a &quot;sick&quot; feeling that was significantly different between drug and control, in the condition where they were instructed to binge eat. This is a subtle feeling without any other symptoms. It is not adverse.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Harry R. Kissileff</name_or_title>
      <organization>St. Luke's/Roosevelt Hospital</organization>
      <phone>212-523-4200</phone>
      <email>hrk2@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

